Omnyx initiates research testing of digital pathology platform

GE Healthcare and UPMC announced today that their imaging joint venture, Omnyx™, is initiating clinical research testing of a breakthrough digital pathology platform that is expected to help transform the 125-year-old practice of pathologists using glass slides. By digitizing the slides and corresponding workflow, the Omnyx technology is intended to do what a traditional microscope cannot -- unite an entire pathology department and improve collaboration, communication and efficiency, with the potential for better patient care. Omnyx has initiated research testing of the technology at three sites in the U.S. and a fourth in Canada.

“By partnering with UPMC we are combining our technical innovation with UPMC's expertise and clinical insight to modernize and bring pathology into the 21st century - accelerating processes, cutting diagnosis times and delivering relief to anxious patients, overworked pathologists and resource-challenged hospitals.”

The breakthrough technology is part of GE Healthcare's $6 billion healthymagination initiative to improve cost, quality and access in healthcare, and another example of GE Healthcare's commitment to investing in innovative bioscience technologies. The Omnyx joint venture was inspired in 2008 by a ground-breaking discovery at GE Healthcare's Global Research Center, where scientists developed a patented dual-camera scanning technology that can digitize glass pathology slides at a fast pace without loss of optical quality.

The new technology - which will be a truly integrated digital pathology solution - is a combination of patented scanners that boost scan speed by using one camera to scan the slide and a second to simultaneously focus, new imaging software for highest-quality images, and an information technology backbone that digitizes a pathology department's workflow. The digital tools are designed to transform the practice of pathologists using glass slides, microscopes and manual paperwork to advance patient cases.

"The Omnyx technology was created by pathologists, for pathologists," said Gene Cartwright, CEO of Omnyx. "It is a uniquely integrated digital pathology technology to digitize the entire pathology workflow, and is expected to help improve efficiency, enhance quality and bring about faster diagnoses for patients. Pathologists are a cornerstone in the diagnosis and treatment plans for patients, and the development of this system has the potential to further enhance their role. We expect that Omnyx will provide a route for the field to adopt digitization, thereby reaping the cost savings, increased access and quality benefits that other fields, like radiology, have enjoyed since going digital."

"Through healthymagination, we want to marry what's possible with technology with what's needed to deliver better healthcare to more people," said Mike Barber, vice president of healthymagination, GE Healthcare. "By partnering with UPMC we are combining our technical innovation with UPMC's expertise and clinical insight to modernize and bring pathology into the 21st century - accelerating processes, cutting diagnosis times and delivering relief to anxious patients, overworked pathologists and resource-challenged hospitals."

UPMC, Montefiore Medical Center, Stanford University Medical Center and University Health Network are currently installing, testing and providing feedback on the research Omnyx platform, and will collect data for an FDA submission. GE Healthcare and UPMC have invested $40 million to-date. The digital pathology market is expected to grow to $2 billion over the next several years.

The potential advantages of digital pathology

"Today, studies show an increased need for collaboration in diagnosis in pathology. Given the inherent collaborative limitations of glass slides - the fact that I have to ship it to someone else to review - these consultations with colleagues are difficult, time-intensive and limited," said George Michalopoulos, M.D., Ph.D., professor and chairman of the Department of Pathology at the University of Pittsburgh School of Medicine and pathologist at UPMC. "An integrated digital pathology solution will allow pathologists to quickly share cases with the click of a button, increasing collaboration among specialists and access for rural hospitals."

An integrated digital pathology solution could help enhance the quality of care for patients by:

  • Increasing the efficiency of the pathology process.
  • Increasing access by facilitating real-time consultation with specialists, regardless of the patient or specialist's location.
  • Facilitating more collaboration among pathologists on patient cases.

Pathology of today and tomorrow

For more than 125 years, pathology has relied on microscopes as its primary tool to determine diagnosis and prognosis. The Omnyx integrated digital pathology technology is expected to help enable pathologists to realize the advantages of the digital age like many of their medical peers, such as radiologists.

"Digitizing pathology is the next big step for the industry - it's critical in revolutionizing the practice to keep up with the digital age," said Sylvia Asa, pathologist-in-chief and medical director at the Omnyx research site University Health Network (Canada). "At the University Health Network, in addition to being more efficient, we will be able to collaborate in new ways, which will be exciting for our doctors and good for our patients who deserve the same level of medical care regardless of their location."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine